NAUTILUS BIOTECHNOLOGY INC (NAUT) Stock Price & Overview

NASDAQ:NAUTUS63909J1088

Current stock price

3.48 USD
-0.3 (-7.94%)
Last:

The current stock price of NAUT is 3.48 USD. Today NAUT is down by -7.94%. In the past month the price increased by 43.8%. In the past year, price increased by 292.11%.

NAUT Key Statistics

52-Week Range0.62 - 4.3101
Current NAUT stock price positioned within its 52-week range.
1-Month Range2.17 - 4.3101
Current NAUT stock price positioned within its 1-month range.
Market Cap
440.429M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.47
Dividend Yield
N/A

NAUT Stock Performance

Today
-7.94%
1 Week
+14.85%
1 Month
+43.80%
3 Months
+75.76%
Longer-term
6 Months +319.88%
1 Year +292.11%
2 Years +18.37%
3 Years +25.63%
5 Years N/A
10 Years N/A

NAUT Stock Chart

NAUTILUS BIOTECHNOLOGY INC / NAUT Daily stock chart

NAUT Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to NAUT. When comparing the yearly performance of all stocks, NAUT is one of the better performing stocks in the market, outperforming 98.81% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NAUT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NAUT. No worries on liquidiy or solvency for NAUT as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NAUT Earnings

Next Earnings DateApr 27, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$0.11
Revenue Reported
EPS Surprise 22.97%
Revenue Surprise %

NAUT Forecast & Estimates

8 analysts have analysed NAUT and the average price target is 4.08 USD. This implies a price increase of 17.24% is expected in the next year compared to the current price of 3.48.


Analysts
Analysts85
Price Target4.08 (17.24%)
EPS Next Y-19.36%
Revenue Next YearN/A

NAUT Groups

Sector & Classification

Index Membership

NAUT Financial Highlights

Over the last trailing twelve months NAUT reported a non-GAAP Earnings per Share(EPS) of -0.47. The EPS increased by 16.07% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-59.00M
Industry RankSector Rank
PM (TTM) N/A
ROA -30.87%
ROE -37.59%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%21.43%
Sales Q2Q%N/A
EPS 1Y (TTM)16.07%
Revenue 1Y (TTM)N/A

NAUT Ownership

Ownership
Inst Owners33.52%
Shares126.56M
Float71.39M
Ins Owners32.29%
Short Float %0.55%
Short Ratio1.84

About NAUT

Company Profile

NAUT logo image Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. The company is headquartered in Seattle, Washington and currently employs 130 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The firm is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The firm's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

Company Info

IPO: 2020-08-07

NAUTILUS BIOTECHNOLOGY INC

2701 Eastlake Ave East

Seattle WASHINGTON US

CEO: Adam Stone

Employees: 130

NAUT Company Website

NAUT Investor Relations

Phone: 12063332001

NAUTILUS BIOTECHNOLOGY INC / NAUT FAQ

What does NAUT do?

Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. The company is headquartered in Seattle, Washington and currently employs 130 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The firm is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The firm's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.


What is the current price of NAUT stock?

The current stock price of NAUT is 3.48 USD. The price decreased by -7.94% in the last trading session.


Does NAUTILUS BIOTECHNOLOGY INC pay dividends?

NAUT does not pay a dividend.


How is the ChartMill rating for NAUTILUS BIOTECHNOLOGY INC?

NAUT has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the sector and industry classification for NAUTILUS BIOTECHNOLOGY INC?

NAUTILUS BIOTECHNOLOGY INC (NAUT) operates in the Health Care sector and the Life Sciences Tools & Services industry.


Would investing in NAUTILUS BIOTECHNOLOGY INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NAUT.


How many employees does NAUTILUS BIOTECHNOLOGY INC have?

NAUTILUS BIOTECHNOLOGY INC (NAUT) currently has 130 employees.